Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/27/2026 | $48.00 | Overweight | Piper Sandler |
| 12/3/2025 | $50.00 | Buy | Lake Street |
| 12/3/2025 | $60.00 | Buy | H.C. Wainwright |
| 11/25/2025 | $57.00 | Buy | Roth Capital |
| 9/2/2025 | $50.00 | Outperform | Oppenheimer |
DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. The company will hold a conference call followed by a question-and-answer period at 8:00 a.m. Eastern Time. Details for the conference call can be found below: Date:Thursday, March 19, 2026Time: 8:00 a.m. Eastern TimeToll Free: 1-877-451-6152International:1-201-389-0879Conf.ID: 13758894 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753536&tp_key=4e91699655 A
DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced that its CEO, Scott Plesha, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 10:00 a.m. Eastern Time. The Pelthos management team is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer representative. The webcast of Mr. Plesha's presentation will be available at: https://event.summitca
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE:PTHS) ("Pelthos"), with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™ (berdazimer) topical gel, an FDA-approved treatment of molluscum contagiosum, a common skin infection characterized by small bumps or lesions. ZELSUVMI delivers nitric oxide directly to the affected skin or tissue via the Nitricil platform, which enables the gel to slowly a
4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
Piper Sandler initiated coverage of Pelthos Therapeutics Inc. with a rating of Overweight and set a new price target of $48.00
Lake Street initiated coverage of Pelthos Therapeutics Inc. with a rating of Buy and set a new price target of $50.00
H.C. Wainwright initiated coverage of Pelthos Therapeutics Inc. with a rating of Buy and set a new price target of $60.00
SCHEDULE 13G/A - Pelthos Therapeutics Inc. (0001919246) (Subject)
424B3 - Pelthos Therapeutics Inc. (0001919246) (Filer)
EFFECT - Pelthos Therapeutics Inc. (0001919246) (Filer)
DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelthos' 2026 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation or removal. Also, effective immediately, Mr. Einhorn will also serve on the Audit Committee and the Compensation Committee of the Pelthos Board of Directors. Mr. Einhorn brings ext
The Moms Against Molluscum movement aims to empower families impacted by molluscum to share their personal stories and encourage others to join the conversationMolluscum is a highly contagious skin infection affecting 16.7 million Americans, mainly childrenMomsAgainstMolluscum.com will offer new resources to support moms, parents, and other caregivers of molluscum patients DURHAM, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced the launch of Moms Against Molluscum, a movement to unite mothers, parents, and other careg
Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and olderCompletes build-out of essential management operational infrastructure and hires 50 territory sales managers DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient nee
DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. The company will hold a conference call followed by a question-and-answer period at 8:00 a.m. Eastern Time. Details for the conference call can be found below: Date:Thursday, March 19, 2026Time: 8:00 a.m. Eastern TimeToll Free: 1-877-451-6152International:1-201-389-0879Conf.ID: 13758894 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753536&tp_key=4e91699655 A
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older. T
Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million in net revenues 2,716 ZELSUVMI units prescribed by 1,169 unique prescribers in the third quarter of fiscal 2025 DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos" or the "Company"), today announced its financial results for the three and nine months ended September 30, 2025, which can be found at the Financial Results section of